|
Jul 24
|
Exagen Inc. (XGN): A Bull Case Theory
|
|
Jul 24
|
Exagen (XGN) Soars 5.5%: Is Further Upside Left in the Stock?
|
|
Jul 17
|
Exagen Inc. Appoints Chas McKhann to Board of Directors
|
|
Jul 15
|
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
|
|
Jun 29
|
Exagen Insider Ups Holding During Year
|
|
Jun 23
|
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
|
|
Aug 29
|
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
|
|
Aug 26
|
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
|
|
Jun 13
|
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
|
|
May 15
|
Exagen Inc (XGN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Margin ...
|
|
May 14
|
Exagen First Quarter 2024 Earnings: Beats Expectations
|
|
May 13
|
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 13
|
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
|
|
Apr 30
|
Exagen to Announce First Quarter 2024 Results on May 13, 2024
|
|
Apr 26
|
Exagen Inc. Announces Changes to the Board of Directors
|
|
Mar 21
|
Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Annual Report
|
|
Mar 20
|
Exagen Full Year 2023 Earnings: Beats Expectations
|
|
Mar 19
|
Exagen Inc. (NASDAQ:XGN) Q4 2023 Earnings Call Transcript
|
|
Mar 19
|
Q4 2023 Exagen Inc Earnings Call
|
|
Mar 18
|
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
|